OCX רווחיות מכירות גולמית OncoCyte Corp

סמלים רשמיים של חברת OncoCyte Inc (OCX)

Due to its independence from global economic cycles, OncoCyte Corporation (OCX) demonstrates resilience as a defensive asset. The company is developing molecular tests for early tumor screening, and management aims to integrate these systems into insurance programs. The gross margin level clearly illustrates the business's operational efficiency, while 10.50 reflects the latest value of the metric.

OncoCyte Corp. (OCX): רווחיות גולמית מ-04.07.2022 עד 18.06.2025

פילוחי מדדים מקיפים ואנליטיקה עבור OncoCyte Corp (OCX)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח מסכם של החברה:OncoCyte - OCX
מוצר עיקרי של OncoCyte

To select high-quality assets, an investor must evaluate the efficiency of the operating model through fundamental metrics. Gross margin determines the share of revenue minus direct production costs, reflecting the business's ability to generate profit before accounting for administrative expenses. Bio-waste optimization and the digitalization of diagnostics at OncoCyte Corporation (OCX) directly impact the reduction of cost of goods sold, which is clearly evidenced by the trend in the gross margin share.